Navigation Links
Senator James Sasser, Former Ambassador to China, Joins Neuralstem Advisory Board
Date:2/12/2009

ROCKVILLE, Md., Feb. 12 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Alternext US: CUR) announced today that James Sasser, former Senator (D-Tennessee) and former Ambassador to the People's Republic of China, has joined the Neuralstem Advisory Board and will serve as senior advisor on China.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO )

Senator Sasser was elected to the United States Senate from Tennessee in 1976 where he served for eighteen years. During that time, Senator Sasser served as Chairman of the Senate Budget Committee as well as Chairman of various subcommittees on the Appropriations Committee, the Banking Committee and the Governmental Affairs committee. In 1995, Senator Sasser was appointed a Fellow at the Kennedy School at Harvard University. While at Harvard, he was appointed Ambassador to the People's Republic of China by President Bill Clinton and served in that capacity for almost four years. He played a pivotal role in stabilizing Sino-US relations and traveled with President Jiang Zemin on his historic State visit to the United States.

"We are extremely proud and excited to have Senator Sasser come on board," said Neuralstem President & CEO Richard Garr. "The company is deeply committed to developing and commercializing our cell therapies in China. Senator Sasser brings an unmatched wealth of knowledge and experience with both the Chinese business and government communities." Neuralstem is in talks with leading medical facilities in China, where the company intends to target spinal cord injury.

"I am excited to help Neuralstem move forward in China," said Senator Sasser. "This new technology is a leading example of American innovation, and has the potential to help so many people all over the world. I am looking forward to being a part of that."

Senator Sasser also serves on the Board of Trustees of the National Geographic Society, on the Board of the Elliott School of International Relations at George Washington University and is a member of the Council on Foreign Relations. He is presently a senior advisor to FedEx Corporation and senior counselor to APCO Worldwide in Washington, DC. He has served as a consultant to other US corporations doing business in China, including Ford Motor Company, the former Unocal Corporation, and Brown-Forman Corporation. Senator Sasser was educated at Vanderbilt University where he received a Bachelor of Arts degree in 1958 and a Doctor of Jurisprudence degree from Vanderbilt Law School in 1961. In 1998, Senator Sasser was selected as a distinguished alumnus of Vanderbilt Law School. He has also served in the U.S. Marine Corps.

About Neuralstem

Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. Major Central Nervous System diseases targeted by the Company with research programs currently underway include: Ischemic Spastic Paraplegia, Traumatic Spinal Cord Injury, Huntington's disease and Amyotrophic Lateral Sclerosis (ALS). The Company filed an IND (Investigational New Drug) application with the FDA for ALS clinical trials in December, 2008, and has entered into a collaborative agreement with Albert-Ludwigs-University, in Freiburg, Germany, to develop clinical trials for Huntington's disease.

In pre-clinical work, the company's cells have extended the life of rats with ALS (Lou Gehrig's disease) as reported the journal TRANSPLANTATION, in collaboration with Johns Hopkins University researchers, and also reversed paralysis in rats with Ischemic Spastic Paraplegia, as reported in NEUROSCIENCE on June 29, 2007, in collaboration with researchers at University of California San Diego.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward- looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10- KSB for the year ended December 31, 2007 and the quarterly report on form 10-Q for the period ended September 30, 2008.


'/>"/>
SOURCE Neuralstem, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. U.S. Senator Arlen Specter Addresses Constituents on Americas Healthcare Crisis
2. FRC Applauds the Withdrawal of Senator Daschle for HHS
3. Comment of Senator Patrick Leahy on President Obamas Decision to Reverse The Mexico City Policy
4. Madison-Area Optometrists Partner With Senator Kohl in Improving Infant Eye and Vision Care
5. Senator Sam Brownback and Rep. Cathy McMorris Rodgers to Speak at Blogs for Life 2009
6. Lung Cancer Alliance Hails Massachusetts State Senator for Taking Lead on Lung Cancer
7. Senators Lugar, Dodd, Boxer and Representatives Lee and McCollum Receive GAC Childrens Champion Award
8. Senator Schumer Speaks to 4,900 AARP Members Pledging Bipartisan Action on Nations Health and Economic Crises
9. Senator Reid, Reps. Slaughter and DeGette Introduce the Prevention First Act
10. US Oncology Applauds Senator Daschles Appointment as Director of President-Elect Obamas New White House Office of Health Reform
11. Comment of Senator Patrick Leahy (D-Vt.) on President-elect Obamas Choice of Former Senator Tom Daschle to Head The Department of Health and Human Services and A New White House Office of Health Reform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... Houston, TX (PRWEB) , ... April 26, 2017 ... ... open data set that describes the adoption of e-prescribing as measured in Part ... different individual prescribers deliver prescriptions to pharmacies, either using e-prescribing, faxes or paper. ...
(Date:4/26/2017)... ... , ... Miami native and local periodontist Dr. John Paul Gallardo ... back in 1991 that this journey would have taken me into so many learning ... Dr. Gallardo has pioneered implant dentistry innovation, evolving into an internationally recognized leader in ...
(Date:4/26/2017)... , ... April 26, 2017 , ... ... performance, is proud to announce that it has received 510(k) clearance from the ... MyoCycle Home and the MyoCycle Pro. , Both devices are stationary cycling systems ...
(Date:4/25/2017)... ... 25, 2017 , ... A stressful work environment can hurt the physical and ... and performance in the workplace. The goal of Clearview Resolution Services has always been ... April, Clearview Resolution Services will be shutting down the office early on Fridays. The ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... modern procedure that achieves results in a fraction of the time as traditional ... NV, with Significance Dental Specialists, now offers this revolutionary treatment with or without ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a ... significant unmet medical needs, today announced that it ... product development program, based on its proprietary self-delivering ... Dermatology (SID) 76 th Annual Meeting.  The ... sciences relevant to skin health and disease through ...
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... "Global Pharmacogenomics Market Size, Market Share, Application Analysis, Regional Outlook, ... 2024" report to their offering. ... The global pharmacogenomics market was valued at US$ ... 11,938.8 Mn by 2024, expanding at a CAGR of 5.6% ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the highest market ... segment is likely to create absolute $ opportunity of a ... By the end of 2027, Cardiology Devices segment is projected ... expanding at a CAGR of 18.4% over the forecast period. ... reprocessed medical devices market in terms of revenue ...
Breaking Medicine Technology: